Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. The progression
of renal lesions to fibrosis involves several mechanisms, among which the inhibition of …

Notwithstanding the ongoing coronavirus disease-2019 (Covid-19) pandemic, information
on its clinical presentation and prognosis in recipients of a kidney transplant remain scanty. …

Background Kidney transplant recipients and patients receiving hemodialysis are
immunocompromised populations that are prioritized for COVID-19 vaccination but were excluded …

1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19
vaccine. N Engl J Med. 2020; 383: 2603-2615. 2. Baden LR, El Sahly HM, Essink B, et al. …

Objectives Cytomegalovirus (CMV) drug resistance is a therapeutic challenge in the transplant
setting. No longitudinal cohort studies of CMV resistance in a real-life setting have been …

Background Treatment of acute antibody-mediated rejection (AMR) is based on a combination
of plasma exchange (PE), IVIg, corticosteroids (CS), and rituximab, but the place of …

Purpose Post-transplantation lymphoproliferative disorder (PTLD) is associated with
significant mortality in kidney transplant recipients. We conducted a prospective survey of the …

Objectives: The aims of this study were (i) to investigate the population pharmacokinetics of
tacrolimus in renal transplant recipients, including the influence of biological and …

End stage kidney disease increase the risk of COVID-19 related death but how the kidney
replacement strategy should be adapted during the pandemic is unknown. Chronic …

Background Atypical hemolytic uremic syndrome (HUS) is associated with high recurrence
rates after kidney transplant, with devastating outcomes. In late 2011, experts in France …